参考文献/References:
[1] Naghavi M, Wang H, Lozano R, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015,385(9963): 117-171.
[2] 高晓津, 杨进刚, 杨跃进, 等. 中国AMI患者心血管危险因素分析[J]. 中国循环杂志, 2015,3:206-210.
[3] Lippi G, Avanzini P, Dipalo M, et al. Influence of hemolysis on troponin testing: studies on Beckman Coulter UniCel Dxl 800 Accu-TnI and overview of the literature[J]. Clin Chem Lab Med, 2011,49(12):2097-2100.
[4] Bandman E. Contractile protein isoforms in muscle development[J].Dev Biol, 1992,154(2):273-283.
[5] Kurz K, Schild C, Isfort P, et al. Serial and single time-point measurements of cardiac troponin T for prediction of clinical outcomes in patients with acute ST-segment elevation myocardial infarction[J]. Clin Res Cardiol,2009,98(2):94-100.
[6] Shah R, Selter J, Wang Y, et al. Association of troponin status with guideline-based management of acute myocardial infarction in older persons[J]. Arch Intern Med,2007,167(15):1621-1628.
[7] Thielmann M, Massoudy P, Neuhauser M, et al. Prognostic value of preoperative cardiac troponin I in patients undergoing emergency coronary artery bypass surgery with non-ST-elevation or ST-elevation acute coronary syndromes[J]. Circulation,2006,114(1):1448-1453.
[8] Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain[J]. Nature,1988,332(3):78-81.
[9] Hall C. Essential biochemistry and physiology of(NT-pro)BNP[J]. Eur J Heart Fail,2004,6(3):257-260.
[10] Wu CJ, Chang HW, Hung WC, et al. N-terminal pro-brain natriuretic peptide is a biomarker of congestive heart failure and predictive of 30-day untoward clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention[J]. Circ J,2006,70(2):163-168.
[11] Pesaro AE, Katz M, Caixeta A, et al. Prognostic value of serial brain natriuretic peptide measurements in patients with acute myocardial infarction[J]. Cardiology, 2015,131(2):116-121.
[12] Francis T,Tillett WS. Cutaneous reactions in rabbits to the type-specific capsular polysaccharides of pneumococcus[J]. J Exp Med,1931,54(4):587-596.
[13] Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease[J]. Nature,2006,440(4):1217-1221.
[14] Wang J, Tang B, Liu X, et al. Increased monomeric CRP levels in acute myocardial infarction:a possible new and specific biomarker for diagnosis and severity assessment of disease[J]. Atherosclerosis,2015,239(2):343-349.
[15] Mlakar P, Salobir B, Cobo N, et al. The effect of short-term cardiac rehabilitation after acute myocardial infarction on high-sensitivity C-reactive protein[J]. Metab Syndr Relat Disord,2014,12(2):149-155.
[16] Aseri ZA, Habib SS, Alhomida AS, et al. Relationship of high sensitivity C-reactive protein with cardiac biomarkers in patients presenting with acute coronary syndrome[J]. J Coll Physicians Surg Pak,2014,24(6):387-391.
[17] Ahmed K, Jeong MH, Chakraborty R, et al. Prognostic impact of baseline high-sensitivity C-reactive protein in patients with acute myocardial infarction undergoing percutaneous coronary intervention based on body mass index[J]. Korean Circ J,2012,42(3):164-172.
[18] Yellon DM,Hausenloy DJ. Myocardial reperfusion injury[J]. N Engl J Med, 2007,357(9):1121-1135.
[19] Zhang K, Zhang XC, Mi YH, et al. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction[J]. Chin Med J(Engl),2013,126(19):3628-3631.
[20] Weir RA, Miller AM, Murphy GE, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction[J]. J Am Coll Cardiol,2010,55(3):243-250.
[21] Khan SQ, Ng K, Dhillon O, et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction[J]. Eur Heart J, 2009,30(9):1057-1065.
[22] Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output[J]. Nature,2008,455(7209):64-71.
[23] Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA:a novel potential biomarker for early diagnosis of acute myocardial infarction in humans[J]. Eur Heart J,2010,31(6):659-666.
[24] Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome[J]. J Mol Cell Cardiol,2011,51(5):872-875.
[25] Fichtlscherer S, de Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease[J]. Circ Res,2010,107(7):677-684.
[26] Bauersachs J,Thum T. Biogenesis and regulation of cardiovascular microRNAs[J]. Circ Res,2011,109(3):334-347.
[27] Lindahl B. Acute coronary syndrome—the present and future role of biomarkers[J]. Clin Chem Lab Med,2013,51(9):1699-1706.
[28] Li Z, Lu J, Luo Y, et al. High association between human circulating microRNA-497 and acute myocardial infarction[J]. Sci World J,2014,2014:931845.
[29] Peng L, Chun-guang Q, Bei-fang L, et al. Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction[J]. Diagn Pathol,2014,9(1):89.
[30] Rapezzi C, Biagini E, Branzi A. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes:the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology [J]. Eur Heart J,2008,29(2):277-278.
[31] Ferraro S, Marano G, Biganzoli EM, et al. Prognostic value of cystatin C in acute coronary syndromes:enhancer of atherosclerosis and promising therapeutic target[J]. Clin Chem Lab Med,2011,49(9):1397-1404.
[32] Kilic T, Oner G, Ural E, et al. Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome[J]. Atherosclerosis, 2009,207(2):552-558.
[33] Iribarren C, Phelps BH, Darbinian JA, et al. Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction:a prospective nested case-control study[J]. BMC Cardiovasc Disord,2011,11(6):31.
[34] Shibata R, Numaguchi Y, Matsushita K, et al. Usefulness of adiponectin to predict myocardial salvage following successful reperfusion in patients with acute myocardial infarction[J]. Am J Cardiol,2008,101(12):1712-1715.
[35] Løgstrup BB, Høfsten DE, Christophersen TB, et al. Microvascular dysfunction is associated with plasma osteoprotegerin levels in patients with acute myocardial infarction[J]. Coron Artery Dis,2013,24(6):487-492.
[36] Devaux Y, Vausort M, Azuaje F, et al. Low levels of vascular endothelial growth factor B predict left ventricular remodeling after acute myocardial infarction[J]. J Card Fail,2012,18(4):330-337.
相似文献/References:
[1]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(1):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]晏露 李欣 柳志红.不同生物标志物在急性肺血栓栓塞症中的应用价值[J].心血管病学进展,2019,(5):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
YAN Lu,LI Xin,LIU Zhihong.The unction of Different Biomarkers in Acute Pulmonary Embolism[J].Advances in Cardiovascular Diseases,2019,(1):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
[4]刘壮壮 黄宇理.心力衰竭生物标志物的研究进展[J].心血管病学进展,2020,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
LIU Zhuangzhuang,HUANG Yuli.Biomarkers for Heart Failure[J].Advances in Cardiovascular Diseases,2020,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
[5]王同霞 陈章荣.可溶ST2与心力衰竭患者预后的评价[J].心血管病学进展,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
WANG Tongxia,CHEN Zhangrong.Prognosis of Heart Failure Patients and Soluble ST2[J].Advances in Cardiovascular Diseases,2020,(1):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
[6]冯小梅 李彦红.Ⅰ型前胶原羧基端肽和Ⅲ型前胶原氨基端肽在心肌纤维化的研究进展[J].心血管病学进展,2020,(5):517.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.018]
FENG Xiaomei,LI Yanhong.PCP and PNP in Myocardial Fibrosis[J].Advances in Cardiovascular Diseases,2020,(1):517.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.018]
[7]李谧 李琳.生长分化因子-15在心房颤动中的研究及应用进展[J].心血管病学进展,2020,(7):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]
LI Mi,LI Lin.Research and Application of Growth Differentiation Factor-15 in Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(1):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]
[8]于博文 修成奎 王雪 杨静 雷燕.内皮微粒在临床中的研究进展及应用[J].心血管病学进展,2021,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
YU Bowen,XIU Chengkui,WANG Xue,et al.Research Progress and Application of Endothelial Microparticles in Clinic[J].Advances in Cardiovascular Diseases,2021,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[9]刘月娥 关秀茹.循环miRNA作为冠心病潜在生物标志物的研究进展[J].心血管病学进展,2021,(2):171.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.019]
LIU Yuee,GUAN Xiuru.Research Progress of Circulating Mirna as a Potential Biomarker of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2021,(1):171.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.019]
[10]孙悦宁 富路.左心室逆重构在心力衰竭中的研究新进展[J].心血管病学进展,2021,(6):525.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.012]
SUN Yuening,FU Lu.Research Progress of Left Ventricular Reverse Remodeling in Heart Failure[J].Advances in Cardiovascular Diseases,2021,(1):525.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.012]